Transitional cell cancer of the renal pelvis and ureter – Diagnostics – Overview of Information and Clinical Research

Transitional cell cancer of the renal pelvis and ureter is a rare disease that mainly affects older adults, and finding it early can make a significant difference in treatment outcomes. Understanding which tests doctors use to identify this cancer, and how these tests work, helps patients feel more prepared and less anxious when facing a possible diagnosis.

Introduction: Who Should Seek Diagnostic Testing

If you notice blood in your urine, even if it only happens once or twice, it is important to see a doctor right away. Blood in the urine, called hematuria, is the most common early warning sign of transitional cell cancer in the upper urinary tract. This symptom does not always mean cancer is present, but it should never be ignored.^[1]

You should also consider seeing a healthcare provider if you experience back pain that does not go away, especially if it occurs on one side between your ribs and hips. Other symptoms that deserve medical attention include pain or cramps in the side or back, unusual fatigue, unexplained weight loss, frequent urination, or pain or burning when you urinate. These symptoms can be caused by many conditions, but only a doctor can determine what is causing them.^[1]

People who have previously had bladder cancer are at higher risk of developing transitional cell cancer in the renal pelvis or ureter. If you have this history, regular follow-up appointments and monitoring are especially important. Doctors recommend that anyone with bladder cancer in the past stay alert for new symptoms and report them promptly. The same cells that line the bladder also line the renal pelvis and ureters, so cancer can develop in these areas after bladder cancer treatment.^[3]

Certain groups of people face higher risk and may benefit from earlier or more frequent screening. Smokers, people over age 65, and those who have worked with chemicals used in dyes, rubber, leather, paint, or textiles should be particularly watchful for symptoms. Men are at higher risk than women. If you have Lynch syndrome, a genetic condition that increases cancer risk, your doctor may recommend regular monitoring even without symptoms.^[1]^[7]

⚠️ Important

Even if blood in your urine appears only once and then stops, you should still contact a doctor. Sometimes early-stage cancers cause bleeding that comes and goes, and waiting to see if it happens again can delay important diagnosis and treatment.

Classic Diagnostic Methods for Identifying the Disease

Urine Tests

When you visit your doctor with symptoms, the first test is often a simple urine analysis, called urinalysis. Your doctor will examine a sample of your urine in a laboratory to check for blood, infection, or other abnormalities. Even if you cannot see blood with your naked eye, laboratory tests can detect tiny amounts of blood cells that may indicate a problem.^[7]

Doctors may also perform a special urine test that looks for cancer cells. This is called urine cytology. A laboratory specialist examines your urine sample under a microscope to see if any cells look abnormal or cancerous. While this test is helpful, it is not perfect. Sometimes it can miss cancer cells, especially if the cancer is low-grade, meaning the cells look more normal. Therefore, doctors usually combine urine tests with other diagnostic methods to get a complete picture.^[7]

Imaging Tests

Imaging tests allow doctors to see inside your body without surgery. A CT scan (computed tomography scan) is one of the most important imaging tools for diagnosing transitional cell cancer of the renal pelvis and ureter. During a CT scan, you lie on a table that slides into a large machine. The machine takes many X-ray pictures from different angles, and a computer combines these images to create detailed cross-sectional views of your kidneys, ureters, and surrounding areas.^[7]

A specialized type of CT scan called a CT urogram is particularly useful for examining the urinary tract. Before the scan, you receive a special dye, called contrast material, through an intravenous line in your arm. This dye travels through your bloodstream to your kidneys and urinary tract, making these structures show up more clearly on the images. The contrast helps doctors see tumors, blockages, or other abnormalities in the renal pelvis and ureters.^[7]

Another imaging test is ultrasound, which uses sound waves to create pictures of the inside of your body. While ultrasound is less detailed than CT scans for viewing the ureters, it can help doctors see masses or blockages in the kidneys. Ultrasound is painless and does not use radiation.^[7]

An older test called intravenous pyelogram (IVP) may still be used in some situations. This test also uses contrast dye and X-rays to see the urinary system. The dye makes blockages or tumors in the kidneys, ureters, and bladder visible on X-ray images. However, CT urograms have largely replaced IVP because they provide more detailed information.^[7]

Scope Examinations

To look directly inside your urinary tract, doctors use thin, flexible tubes with lights and cameras on the end. These instruments are called scopes, and the procedures have specific names depending on which part of the body is examined.

A cystoscopy allows the doctor to look inside your bladder. The doctor gently inserts the scope through your urethra (the tube that carries urine out of your body) and into your bladder. This test is important because people with upper urinary tract cancer often also have bladder cancer, or may develop it later. Checking the bladder helps doctors understand the full extent of disease.^[7]

A ureteroscopy is used to examine the ureters and renal pelvis. The doctor passes a thin scope through your urethra and bladder, then up into the ureter and kidney. This allows direct visualization of any tumors or abnormal areas. During this procedure, the doctor can also take small tissue samples, called biopsies, from suspicious areas. These tissue samples are sent to a laboratory where specialists examine them under a microscope to determine if cancer cells are present.^[2]^[6]

However, even with ureteroscopy, it can be difficult to determine exactly how deep a tumor has grown into the wall of the ureter or renal pelvis. This information, called the depth of invasion, is very important for planning treatment. Because of this limitation, doctors often need to combine information from biopsies with imaging tests and other findings to make treatment decisions.^[2]

Blood Tests

While blood tests cannot directly diagnose transitional cell cancer, they provide important information about your overall health and kidney function. Your doctor will check how well your kidneys are working, because this information affects which treatments are safest for you. Blood tests can also reveal anemia (low red blood cell count), which sometimes occurs when cancer causes ongoing bleeding in the urinary tract.^[1]

Understanding the Complete Diagnostic Picture

Diagnosing transitional cell cancer of the renal pelvis and ureter usually requires several different tests. No single test can provide all the answers doctors need. Urine tests might show blood or suspicious cells. Imaging tests reveal the size and location of tumors. Scope examinations allow direct viewing and tissue sampling. Together, these tests help doctors understand not only whether cancer is present, but also how aggressive it is and whether it has spread beyond the renal pelvis or ureter.

After all diagnostic tests are complete, doctors examine the cancer cells under a microscope to determine their grade. Grade describes how abnormal the cancer cells look compared to normal cells. Low-grade cancers have cells that look fairly similar to normal cells and tend to grow slowly. High-grade cancers have very abnormal-looking cells and typically grow and spread more quickly. Grade is one of the most important factors doctors consider when planning treatment.^[2]

Doctors also determine the stage of the cancer, which describes how far the disease has spread. Superficial cancers that stay in the inner lining of the renal pelvis or ureter have the best outlook. Cancers that invade deeply into the wall or spread to nearby lymph nodes or other organs are more advanced and more difficult to treat. The stage helps doctors predict how the cancer might behave and which treatments are most appropriate.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new ways of using existing treatments. If you are considering joining a clinical trial for transitional cell cancer of the renal pelvis and ureter, you will need to undergo specific diagnostic tests to determine if you qualify for the study.

Each clinical trial has its own set of requirements, called eligibility criteria. These criteria ensure that the trial enrolls patients who are most likely to benefit from the experimental treatment and whose results will provide meaningful scientific information. Common tests used to qualify patients for clinical trials include many of the same diagnostic procedures used for initial diagnosis.

Imaging tests such as CT scans are typically required to measure the exact size and location of tumors. Clinical trials often specify that tumors must be a certain size or stage to participate. These baseline measurements are important because researchers need to track whether the tumor shrinks, stays the same, or grows during treatment.

Biopsy results showing the specific type and grade of cancer cells are usually required. Some trials only accept patients with high-grade cancers, while others focus on those with lower-grade disease. The cellular characteristics help researchers understand which patients respond best to the treatment being studied.

Blood tests measuring kidney function are essential for most clinical trials. Experimental treatments may affect the kidneys, so doctors need to know your kidney function is adequate before starting the trial. Tests measuring overall health, including liver function and blood cell counts, are also standard requirements.

Some newer clinical trials test treatments that target specific genetic changes in cancer cells. If you are considering one of these trials, you may need additional testing of your tumor tissue to look for particular genetic markers. These specialized tests examine the DNA in cancer cells to see if they have mutations that the experimental drug targets.

Performance status assessments, which measure how well you can carry out daily activities, are another common requirement. Most trials only accept patients who are well enough to tolerate the experimental treatment and complete the study procedures.

⚠️ Important

Clinical trials often require more frequent testing and monitoring than standard treatment. Before joining a trial, make sure you understand the testing schedule and whether the trial requires you to travel to a specific medical center for some or all of your care.

Prognosis and Survival Rate

Prognosis

The outlook for people with transitional cell cancer of the renal pelvis and ureter depends most importantly on how deeply the cancer has invaded the wall of the urinary tract at the time of diagnosis. This factor, called the depth of infiltration, is the single most important piece of information doctors use to predict how the disease will progress. Cancers that remain superficial, staying only in the inner lining without penetrating deeper layers, generally have much better outcomes than those that invade through the wall.^[2]

The grade of the cancer also affects prognosis significantly. Most superficial tumors are well-differentiated, meaning the cancer cells look fairly similar to normal cells and tend to behave less aggressively. In contrast, tumors that invade deeply are usually poorly differentiated, with very abnormal-looking cells that grow and spread more aggressively. Patients with low-grade tumors (grades I and II) typically have better outcomes than those with high-grade tumors (grades III and IV).^[2]^[17]

Another important consideration is the risk of cancer developing elsewhere in the urinary tract. Between 30% and 50% of patients with upper tract transitional cell cancer will later develop bladder cancer. This happens because the same types of cells line the entire urinary tract, from the renal pelvis through the ureters and into the bladder. When cancer develops in multiple locations throughout the urinary tract, it is called diffuse involvement, and this increases the likelihood of bladder cancer to as high as 75%.^[2]^[10]

The chance of developing cancer in the other kidney (contralateral cancer) is lower, occurring in about 2% to 4% of patients. However, this possibility means that patients need long-term monitoring of both kidneys after treatment.^[2]

The stage at which cancer is caught makes an enormous difference in prognosis. When transitional cell cancer of the renal pelvis and ureter is detected early and remains confined to these structures, treatment outcomes are generally very favorable. However, when the cancer has already spread through the wall of the urinary tract or reached distant organs by the time of diagnosis, long-term survival becomes much more challenging.^[1]

Survival Rate

Survival rates for transitional cell cancer of the renal pelvis and ureter vary dramatically based on the stage and depth of the cancer at diagnosis. These cancers are curable in more than 90% of patients when they are superficial and confined to the renal pelvis or ureter. This means that if the cancer is caught early, before it has grown deep into the wall or spread elsewhere, the vast majority of patients can be cured with appropriate treatment.^[2]^[10]

For patients with deeply invasive tumors that remain confined to the renal pelvis or ureter but have penetrated through the inner layers into deeper tissues, the likelihood of cure drops significantly to between 10% and 15%. This dramatic difference highlights how important early detection is for this type of cancer.^[2]^[10]

When cancer has penetrated completely through the wall of the urinary tract or has spread to distant parts of the body (metastasized), patients usually cannot be cured with currently available treatments. However, this does not mean treatment cannot help. Even in advanced stages, treatment can control the disease, relieve symptoms, and improve quality of life for a period of time.^[2]^[10]

It is important to understand that survival statistics are based on groups of patients and represent averages. Individual outcomes can vary considerably based on many factors including your overall health, how well you respond to treatment, the specific characteristics of your cancer, and advances in treatment that occur over time. Your doctor can provide more personalized information based on your specific situation.^[1]

#1 Clinical Trials Search in Europe